Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (Gulu)

Ariel Sobarzo; Allison Groseth; Olga Dolnik; Stephan Becker; Julius Julian Lutwama; Eddie Perelman; Victoria Yavelsky; Majidat Muhammad; Ana I. Kuehne; Robert S. Marks; John M. Dye; Leslie Lobel

doi:10.1093/infdis/jit162

Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (Gulu)

Ariel Sobarzo, Allison Groseth, Olga Dolnik, Stephan Becker, Julius Julian Lutwama, Eddie Perelman, Victoria Yavelsky, Majidat Muhammad, Ana I. Kuehne, Robert S. Marks, John M. Dye, Leslie Lobel

Ben-Gurion University of the Negev

Research output: Contribution to journal › Article › peer-review

Abstract

To better understand humoral immunity following ebolavirus infection, a serological study of the humoral immune response against the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed. An enzyme-linked immunosorbent assay specific for full-length recombinant viral proteins NP, VP30, VP40, and GP_1-649 (GP lacking the transmembrane domain) of Sudan ebolavirus (Gulu) was used as well as a plaque reduction neutralization test. Serum samples from human survivors, which were collected up to 10 years following recovery, were screened and analyzed. Results demonstrate that samples obtained 10 years following infection contain virus-specific antibodies that can neutralize virus. Neutralization correlates well with immunoreactivity against the viral proteins NP, VP30, and GP_1-649. Sera from individuals who died or those with no documented infection but immunoreactive to ebolavirus did not neutralize. This work provides insight into the duration, profile of immunoreactivity, and neutralization capacity of the humoral immune response in ebolavirus survivors.

Original language	American English
Pages (from-to)	299-309
Number of pages	11
Journal	Journal of Infectious Diseases
Volume	208
Issue number	2
DOIs	https://doi.org/10.1093/infdis/jit162
State	Published - 15 Jul 2013

Keywords

antibodies
ebolavirus
epitopes
immune response
sera screening
serological profiling

All Science Journal Classification (ASJC) codes

Infectious Diseases
Immunology and Allergy

Access to Document

10.1093/infdis/jit162

Cite this

Sobarzo, A., Groseth, A., Dolnik, O., Becker, S., Lutwama, J. J., Perelman, E., Yavelsky, V., Muhammad, M., Kuehne, A. I., Marks, R. S., Dye, J. M., & Lobel, L. (2013). Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (Gulu). Journal of Infectious Diseases, 208(2), 299-309. https://doi.org/10.1093/infdis/jit162

@article{84c9a47d1a224a949e33047e936fa547,

title = "Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (Gulu)",

abstract = "To better understand humoral immunity following ebolavirus infection, a serological study of the humoral immune response against the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed. An enzyme-linked immunosorbent assay specific for full-length recombinant viral proteins NP, VP30, VP40, and GP1-649 (GP lacking the transmembrane domain) of Sudan ebolavirus (Gulu) was used as well as a plaque reduction neutralization test. Serum samples from human survivors, which were collected up to 10 years following recovery, were screened and analyzed. Results demonstrate that samples obtained 10 years following infection contain virus-specific antibodies that can neutralize virus. Neutralization correlates well with immunoreactivity against the viral proteins NP, VP30, and GP1-649. Sera from individuals who died or those with no documented infection but immunoreactive to ebolavirus did not neutralize. This work provides insight into the duration, profile of immunoreactivity, and neutralization capacity of the humoral immune response in ebolavirus survivors.",

keywords = "antibodies, ebolavirus, epitopes, immune response, sera screening, serological profiling",

author = "Ariel Sobarzo and Allison Groseth and Olga Dolnik and Stephan Becker and Lutwama, {Julius Julian} and Eddie Perelman and Victoria Yavelsky and Majidat Muhammad and Kuehne, {Ana I.} and Marks, {Robert S.} and Dye, {John M.} and Leslie Lobel",

note = "Funding Information: Financial support. The authors acknowledge the support of the National Institute of Biotechnology in the Negev, Beersheva, Israel, and the Feldman Family Foundation. Potential conflicts of interest. All authors: No reported conflicts.",

year = "2013",

month = jul,

day = "15",

doi = "10.1093/infdis/jit162",

language = "American English",

volume = "208",

pages = "299--309",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "2",

}

Sobarzo, A, Groseth, A, Dolnik, O, Becker, S, Lutwama, JJ, Perelman, E, Yavelsky, V, Muhammad, M, Kuehne, AI, Marks, RS, Dye, JM & Lobel, L 2013, 'Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (Gulu)', Journal of Infectious Diseases, vol. 208, no. 2, pp. 299-309. https://doi.org/10.1093/infdis/jit162

TY - JOUR

T1 - Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (Gulu)

AU - Sobarzo, Ariel

AU - Groseth, Allison

AU - Dolnik, Olga

AU - Becker, Stephan

AU - Lutwama, Julius Julian

AU - Perelman, Eddie

AU - Yavelsky, Victoria

AU - Muhammad, Majidat

AU - Kuehne, Ana I.

AU - Marks, Robert S.

AU - Dye, John M.

AU - Lobel, Leslie

N1 - Funding Information: Financial support. The authors acknowledge the support of the National Institute of Biotechnology in the Negev, Beersheva, Israel, and the Feldman Family Foundation. Potential conflicts of interest. All authors: No reported conflicts.

PY - 2013/7/15

Y1 - 2013/7/15

N2 - To better understand humoral immunity following ebolavirus infection, a serological study of the humoral immune response against the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed. An enzyme-linked immunosorbent assay specific for full-length recombinant viral proteins NP, VP30, VP40, and GP1-649 (GP lacking the transmembrane domain) of Sudan ebolavirus (Gulu) was used as well as a plaque reduction neutralization test. Serum samples from human survivors, which were collected up to 10 years following recovery, were screened and analyzed. Results demonstrate that samples obtained 10 years following infection contain virus-specific antibodies that can neutralize virus. Neutralization correlates well with immunoreactivity against the viral proteins NP, VP30, and GP1-649. Sera from individuals who died or those with no documented infection but immunoreactive to ebolavirus did not neutralize. This work provides insight into the duration, profile of immunoreactivity, and neutralization capacity of the humoral immune response in ebolavirus survivors.

AB - To better understand humoral immunity following ebolavirus infection, a serological study of the humoral immune response against the individual viral proteins of Sudan ebolavirus (Gulu) in human survivors was performed. An enzyme-linked immunosorbent assay specific for full-length recombinant viral proteins NP, VP30, VP40, and GP1-649 (GP lacking the transmembrane domain) of Sudan ebolavirus (Gulu) was used as well as a plaque reduction neutralization test. Serum samples from human survivors, which were collected up to 10 years following recovery, were screened and analyzed. Results demonstrate that samples obtained 10 years following infection contain virus-specific antibodies that can neutralize virus. Neutralization correlates well with immunoreactivity against the viral proteins NP, VP30, and GP1-649. Sera from individuals who died or those with no documented infection but immunoreactive to ebolavirus did not neutralize. This work provides insight into the duration, profile of immunoreactivity, and neutralization capacity of the humoral immune response in ebolavirus survivors.

KW - antibodies

KW - ebolavirus

KW - epitopes

KW - immune response

KW - sera screening

KW - serological profiling

UR - http://www.scopus.com/inward/record.url?scp=84879395546&partnerID=8YFLogxK

U2 - 10.1093/infdis/jit162

DO - 10.1093/infdis/jit162

M3 - Article

SN - 0022-1899

VL - 208

SP - 299

EP - 309

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 2

ER -

Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of sudan ebolavirus (Gulu)

Abstract

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this